Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1623 1693
This examiner grants 38% of resolved cases
Examiner HOI YAN NMN LEE is assigned to Tech Center 1600 and Art Unit 1623. The examiner has reached a final resolution on 83 cases. The data shows an allowance rate of 39.8 percent, which represents the proportion of applications that result in a patent grant rather than an abandonment. This rate provides a primary indicator of the likelihood of success for an application assigned to this examiner in Art Unit 1623.
The median days to allowance for this examiner is 1236. This figure represents the middle point of the time distribution for applications that successfully result in a patent grant. A median of 1236 days offers a specific timeline for practitioners to consider when managing client expectations and filing strategies. Understanding this duration is essential for navigating the procedural requirements of Tech Center 1600.
The interview lift is 75.4 percent. This figure quantifies the change in the probability of allowance when an interview is conducted during the prosecution process. A lift of 75.4 percent suggests that verbal communication with the examiner may significantly influence the final outcome of a case. For the 83 resolved cases analyzed, this statistic serves as a tool for determining whether to request a formal interview.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17297586 | D-PSICOSE CRYSTAL AND PREPARATION METHOD THEREFOR | Non-Final OA | CJ CHEILJEDANG CORPORATION |
| 17621987 | LIQUID PHASE SEPARATION OF 2G SUGARS BY ADSORPTION ON A FAU ZEOLITE HAVING A SI/AL ATOMIC RATIO GREATER THAN 1.5 | Final Rejection | IFP Energies nouvelles |
| 18695914 | DERIVATIVES FROM 2,5,6-TRIMETHYLCYCLOHEX-2-EN-1-OL AS AROMA INGREDIENTS | Non-Final OA | BASF SE |
| 17283728 | ENZYMATIC RNA SYNTHESIS | Non-Final OA | President and Fellows of Harvard College |
| 18045744 | COMPOSITIONS AND METHODS FOR PREDICTING THERAPEUTIC OUTCOME | Non-Final OA | Washington University |
| 18696438 | BACTERIAL CAPSULAR OLIGOSACCHARIDE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Non-Final OA | PEKING UNIVERSITY |
| 18011341 | SAPONIN CONTAINING EXTRACTS PREPARED FROM HESPERALOE USEFUL IN THE TREATMENT OF NON-HUMAN ANIMALS | Non-Final OA | KIMBERLY-CLARK WORLDWIDE, INC. |
| 17995264 | PREPARATION FOR USE AS VASORELAXANT | Non-Final OA | Evonik Operations GmbH |
| 18334457 | LIQUID COMPOSITION | Final Rejection | Shin-Etsu Chemical Co., Ltd. |
| 17925180 | OLEOGEL AND OLEOPASTE COMPOSITIONS AND USES THEREOF | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 17427502 | DEUTERATED MITRAGYNINE ANALOGS AS SAFER OPIOID MODULATORS IN THE MITRAGYNINE CLASS | Final Rejection | Sloan-Kettering Institute for Cancer Research |
| 19003429 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES WITH DIABETES | Non-Final OA | ARIBIO CO., LTD. |
| 18577948 | MULTIPLEXING TARGETING LIGANDS THROUGH CLICK CHEMISTRY AT THE ANOMERIC SITE OF SUGARS | Non-Final OA | ALNYLAM PHARMACEUTICALS, INC. |
| 18030186 | HELICASE INHIBITORS FOR TREATMENT OF MEDICAL DISORDERS | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 17629598 | BIOACTIVE SAPONIN LINKED TO A FUNCTIONAL MOIETY | Final Rejection | Sapreme Technologies B.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy